The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol

One-a-Day HIV Treatments: How Do They Compare? (Infographic)

March 24, 2014

Just one pill a day to control HIV? This once-fanciful idea became a reality in 2006, when Atripla was approved as the first single-tablet HIV medication regimen in the U.S. A single-tablet regimen (STR) contains meds from different drug classes and is a complete day's HIV meds in one pill. Atripla was the sole STR for years -- until Complera came along in 2011, followed by Stribild in 2012.

There are even more STRs for HIV on the horizon; but how do the three that are already available compare to one another? Thanks to the expertise of the folks at AIDS InfoNet and at Positively Aware -- home to the tremendously informative Annual HIV Drug Guide -- there's a wealth of facts and informed opinions available on all three pills, which we've sampled here in this infographic.

This infographic is just a starter guide to learning about these meds. Another great guide is your health care provider; when considering treatment options, please consult her or him.

One-a-Day HIV Treatments: How Do They Compare? (click to enlarge)

Add This Infographic to Your Website or Blog With This Code:

<a href="" target="_blank"><img src="" width="650" height="1616" alt="One-a-Day HIV Treatments: How Do They Compare? (click to enlarge)" border="0"></a> <br>

More From This Resource Center

10 Questions to Ask Yourself Before You Begin HIV Treatment

Are Your HIV Meds Working? Warning Signs and False Alarms

This article was provided by TheBody.
See Also
More on HIV Medications
More on Atripla (Efavirenz/Tenofovir/FTC)


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.